A Message from the Managing Director
The past fiscal year was unlike any other in the prior history of technology commercialization at the University of Pennsylvania. Despite unprecedented operational and logistical challenges caused by the impacts of the pandemic, PCI helped to facilitate a record-breaking year in terms of commercialization activity at Penn that further extends Penn’s already prodigious global technology and innovation impact. PCI also continued its steadfast focus on increased client services through our active faculty outreach and corporate connecting efforts, virtually hosting numerous programs and stakeholder engagement activities.
We remain deeply grateful for the consistent support from Vice Provost for Research Dawn Bonnell and the rest of Penn’s executive leadership led by President Amy Gutmann and hope that our commercialization activities represent a direct reflection of her amazing tenure and legacy as Penn’s President. As a result of the vision articulated in Dr. Gutmann’s ambitious Compact 2022, PCI, Penn, and its research and development community continue to be strongly positioned for technology commercialization and translational partnership.
mRNA vaccine doses administered globally.
Highest numbers of patents ever filed.
Facilitated the highest amount of aggregate licensing revenue at Penn in PCI’s history
Funds raised by Penn-affiliated startups continues to be strong
executed commercial agreements, $1.7 B in annual licensing revenue
Press mentions for PCI programs, startups and partners.
Programs and events hosted by PCI
PCI-facilitated Penn spinouts and Penn-affiliated startups raised or received $560M in venture capital funding
Companies and growing at the Pennovation Works campus
Partner meetings with corporations and external partners